SITC 2022 | Sensitizing poorly differentiated thyroid cancers to TSHR-CART cell therapy with MEK inhibitors
Claudia Manriquez Roman
• 4 Nov 2022
Claudia Manriquez Roman, Mayo Clinic, Rochester, MN, discusses the sensitization of poorly differentiated thyroid cancers to thyroid stimulating hormone receptor (THSR) CAR-T cell therapy via MEK inhibitors. This interview took place at the 37th Annual Meeting of the Society for Immunotherapy in Cancer (SITC 2022) in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
